Premium
Treatment results: Parkinson's disease
Author(s) -
Pollak Pierre,
Fraix Valérie,
Krack Paul,
Moro Elena,
Mendes Alexandre,
Chabardes Stephan,
Koudsie Adnan,
Benabid AlimLouis
Publication year - 2002
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.10146
Subject(s) - deep brain stimulation , subthalamic nucleus , levodopa , dyskinesia , parkinson's disease , medicine , thalamus , physical medicine and rehabilitation , disconnection , neuroscience , psychology , disease , political science , law
Deep brain stimulation (DBS) is a neurosurgical treatment of Parkinson's disease that is applied to three targets: the ventral intermediate nucleus of the thalamus (Vim), the globus pallidus internas (GPi) and the subthalamic nucleus (STN). Vim DBS mainly improves contralateral tremor and, therefore, is being supplanted by DBS of the two other targets, even in patients with tremor dominant disease. STN and GPi DBS improve off‐motor phases and dyskinesias. There is little comparative data between these procedures. The magnitude of the motor improvement seems more constant with STN than GPi DBS. STN DBS allows a decrease in antiparkinsonian drug doses and consumes moderate current. These advantages of STN over GPi DBS are offset by the need for more intensive postoperative management. The DBS procedure has the unique advantage of reversibility and adjustability over time. Patients with young‐onset Parkinson's disease suffering from levodopa‐induced motor complications but still responding well to levodopa and who exhibit no behavioral, mood, or cognitive impairment benefit the most from STN DBS. Adverse effects more specific of the DBS procedure are infection, cutaneous erosion, and lead breaking or disconnection. Intracranial electrode implantation can induce a hematoma or contusion. Most authors agree that the benefit to risk ratio of DBS is favorable. © 2002 Movement Disorder Society